Explain this page
Arphra AIPlain-English read on Bristol-Myers Squibb Company’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00% | -5.56% | -6.56% | -12.74% | +12.75% | +0.85% | +11.50% | -17.15% | -15.91% | -25.48% | +2579.80% |
Aftermarket
LiveLast trade
$54.40
92 sh
Bid
$54.39
1,118 sh
Ask
$54.41
500 sh
Spread
$0.020
Sector & industry today
LiveSectors
- Energy+1.49%
- Technology+1.15%
- Basic Materials+0.94%
- Industrials+0.84%
- Utilities+0.44%
- Real Estate+0.26%
- Consumer Cyclical+0.25%
- Consumer Defensive+0.20%
- Financial Services+0.01%
- Communication Services-0.09%
- Healthcare-0.28%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.11%
- Electronic Gaming & Multimedia-4.11%
- Hardware, Equipment & Parts+3.99%
- Computer Hardware-3.50%
- Oil & Gas Energy+3.49%
- Coal+2.97%
- REIT - Office+2.75%
- Independent Power Producers+2.75%
- Real Estate - Services+2.73%
- Agricultural - Machinery+2.69%
- Copper+2.68%
- Auto - Parts+2.56%
Fair value
Football field →Weighted blend
$443.50
+715.26% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
15bull2bear
±5% threshold
Analyst PT consensus: $62.00 (+13.97%)
Total assets
$90.04B
Total debt
$47.14B
Cash & equiv
$10.21B
Operating CF
$14.16B
Free cash flow
$12.85B
Buybacks
$0
Analyst view
DB · price_targets + analyst_gradesConsensus target
$62.00
+13.97% upside
Low
$40.00
Median
$60.00
High
$75.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Is BMY Undervalued? DCF Says Worth $74gurufocus.com·May 12, 2026
- Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunologyprnewswire.com·May 12, 2026
- Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunologyprnewswire.com·May 12, 2026
- China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 blnreuters.com·May 12, 2026
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adultsbusinesswire.com·May 08, 2026
- Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026businesswire.com·May 06, 2026
- Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™businesswire.com·May 04, 2026
- Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™businesswire.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $11.49B | $2.68B | $1.31 |
| Q4 Dec 2025 | $12.5B | $1.09B | $0.53 |
| Q3 Sep 2025 | $12.22B | $2.2B | $1.08 |
| Q2 Jun 2025 | $12.27B | $1.31B | $0.64 |
| Q1 Mar 2025 | $11.2B | $2.46B | $1.20 |
| Q4 Dec 2024 | $12.34B | $72M | $0.04 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Elkins David V officer: EVP, Chief Financial Officer | Sell | 4,481 | $278.05K | Apr 01, 2026 |
Elkins David V officer: EVP, Chief Financial Officer | Sell | 25,519 | $1.57M | Apr 01, 2026 |
Elkins David V officer: EVP, Chief Financial Officer | Sell | 56,000 | $2.65M | Sep 02, 2025 |
Short Bartie Wendy officer: EVP, Corporate Affairs | Sell | 378 | $16.72K | Aug 02, 2025 |
Hickey Benjamin officer: President, RayzeBio Org. | Sell | 97 | $3.7K | May 09, 2025 |
Hirawat Samit officer: EVP,Chief Med.Offr.,Drug Dev. | Buy | 4,250 | $202.22K | Apr 25, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $48.19B | $12.7B | $7.05B | $3.45 | +14.63% |
| FY 2024 | $48.3B | $9.66B | -$8.95B | $-4.41 | -18.53% |
| FY 2023 | $45.01B | $8.47B | $8.03B | $3.86 | +17.83% |
| FY 2022 | $46.16B | $9.27B | $6.33B | $2.95 | +13.71% |
| FY 2021 | $46.39B | $9.54B | $6.99B | $3.12 | +15.08% |